Immune checkpoint inhibitors have experienced tremendous uptake in the treatment of bladder cancer following their approval for metastatic disease and, in the case of Keytruda, non-muscle-invasive disease. The addition of Merck KGaA / Pfizer’s Bavencio as first-line maintenance therapy for metastatic or unresectable bladder cancer will continue to drive uptake. These therapies have significantly transformed the treatment algorithm for the disease in all lines of therapy, particularly the cisplatin-ineligible population. The approval of novel drug classes, such as Janssen’s first-in-class FGFR inhibitor Balversa (erdafitinib) for patients harboring susceptible FGFR2 or FGFR3 genetic alterations and Astellas / Seagen’s antibody drug conjugate (ADC) Padcev (enfortumab vedotin-ejfv) for locally advanced unresectable or metastatic disease, will further expand physicians’ armamentarium.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Key companies: Astellas / Seagen, AstraZeneca, Bristol Myers Squibb, Genentech / Roche, Janssen, Merck & Co., Merck KGaA / Pfizer
Key drugs: Balversa, Bavencio, Imfinzi, Keytruda, Opdivo, Padcev, Tecentriq